Combination aspirin and clopidogrel for secondary prevention of ischemic stroke

Current Treatment Options in Cardiovascular Medicine

Volumn 15, Issue 3, 2013, Pages 348-359

  Field, Thalia S ^a   Nakajima, Makoto ^b   Benavente, Oscar R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

Author keywords

Antiplatelet; Aspirin; Atrial fibrillation; Cardioembolic; Clinical trials; Clopidogrel; Dipyridamole; Large vessel; Prevention; Small vessel disease; Stroke; TIA

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; IRBESARTAN; PLACEBO; SIMVASTATIN; WARFARIN;

ANTICOAGULANT THERAPY; AORTA ATHEROSCLEROSIS; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CAROTID ARTERY OBSTRUCTION; COMBINATION CHEMOTHERAPY; HEART ATRIUM FIBRILLATION; HUMAN; LACUNAR STROKE; LOADING DRUG DOSE; MICROEMBOLISM; MIDDLE CEREBRAL ARTERY OCCLUSION; MONOTHERAPY; MORTALITY; NEUROIMAGING; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK;

EID: 84877764550     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-013-0241-x     Document Type: Article

References (41)

1. Wang Y. Clopidogrel and aspirin vs aspirin alone for the treatmend of high-risk patients with acute non-disabling cerebrovascular events (CHANCE): a randomized, double-blind, placebo-controlled multicenter trial (Oral Abstract, Late-Breaking Science, International Stroke Conference 2013). http://my.americanheart.org/professional/Sessions/InternationalStrokeConference/ Archive/ISC-2013-Late-Breaking-Science-Oral-Abstracts-UCM-447814-Article.jsp. The preliminary results of the trial; the first to demonstrate a clear benefit of a short course dual antiplatelet therapy for secondary prevention of minor stroke/TIA.
2. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischemic and intracerebral hemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112-23.
3. Feigin VL. Stroke in developing countries: can the epidemic be stopped and outcomes improved? Lancet Neurol. 2007;6(2):94-7.
4. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol. 2007;6(2):182-7.
5. Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JN, et al. Effect of urgent treatment of transient ischemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet. 2007;370(9596):1432-42.
6. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373(9678):1849-60.
7. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1-2):1-13.
8. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole vs aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet. 2006;367(9523):1665-73.
9. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Aspirin and extended-release dipyridamole vs clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238-51.
10. Chandratheva A, Mehta Z, Geraghty OC, Marquardt L, Rothwell PM. Population-based study of risk and predictors of stroke in the first few hours after a TIA. Neurology. 2009;72(22):1941-7.
11. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331- 7.
12. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast assessment of stroke and transient ischemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol. 2007;6(11):961-9.
13. Geeganage CM, Diener HC, Algra A, Chen C, Topol EJ, Dengler R, et al. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke. 2012;43(4):1058-66. An updated systematic review and meta-analysis of single vs dual antiplatelet medication.
14. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin vs aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-17.
15. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation. 2005;111(17):2233-40.
16. Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al. Clopidogrel plus aspirin vs aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomized, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9(5):489-97.
17. Dengler R, Diener HC, Schwartz A, Grond M, Schumacher H, Machnig T, et al. Early treatment with aspirin plus extended-release dipyridamole for transient ischemic attack or ischemic stroke within 24 h of symptom onset (EARLY trial): a randomized, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9(2):159-66.
18. Matias-Guiu J, Davalos A, Pico M, Monasterio J, Vilaseca J, Codina A. Low-dose acetylsalicylic acid (ASA) plus dipyridamole vs dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks. Acta Neurol Scand. 1987;76(6):413-21.
19. Chairangsarit P, Sithinamsuwan P, Niyasom S, Udommongkol C, Nidhinandana S, Suwantamee J. Comparison between aspirin combined with dipyridamole vs aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. Journal of the Medical Association of Thailand =. Chotmaihet thangphaet. 2005;88 Suppl 3:S148-54.
20. Wang Y, Johnston SC. Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen vs aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am Heart J. 2010;160(3):380-6e1.
21. Liu L, Wang D, Wong KS, Wang Y. Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke. 2011;42(12):3651-4.
22. Fisher CM. Lacunes. Small, deep cerebral infarcts. Neurology. 2011;77(24):2104.
23. Thompson CS, Hakim AM. Living beyond our physiological means: small vessel disease of the brain is an expression of a systemic failure in arteriolar function: a unifying hypothesis. Stroke. 2009;40(5):e322-30.
24. Yip S, Benavente O. Antiplatelet agents for stroke prevention. Neurotherapeutics. 2011;8(3):475-87.
25. Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367(9):817-25. This large randomized trial was the first to investigate secondary prevention in a dedicated symptomatic lacunar stroke population.
26. Palacio S, Hart RG, Pearce LA, Benavente OR. Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials. Stroke. 2012;43(8):2157-62. An updated systematic review and meta-analysis examining mortality in dual antiplatelet trials.
27. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010;121(23):2575-83.
28. Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J. 2007;28(18):2200-7.
29. Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin vs aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol. 2009;103(10):1359-63.
30. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology. 2004;62(4):569-73.
31. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al. Stenting vs aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993-1003. This study demonstrates the benefit of aggressive medical management for intracranial stenosis.
32. Powers WJ, Clarke WR, Grubb Jr RL, Videen TO, Adams Jr HP, Derdeyn CP. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial. JAMA. 2011;306(18):1983-92.
33. Haynes RB, Mukherjee J, Sackett DL, Taylor DW, Barnett HJ, Peerless SJ. Functional status changes following medical or surgical treatment for cerebral ischemia. Results of the extracranial-intracranial bypass study JAMA. 1987;257(15):2043-6.
34. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305-16.
35. Mazighi M, Tanasescu R, Ducrocq X, Vicaut E, Bracard S, Houdart E, et al. Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurology. 2006;66(8):1187-91.
36. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke Lancet. 2008;371(9624):1612-23.
37. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066-78.
38. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet. 2006;367(9526):1903-12.
39. Macleod MR, Amarenco P, Davis SM, Donnan GA. Atheroma of the aortic arch: an important and poorly recognized factor in the atiology of stroke. Lancet Neurol. 2004;3(7):408-14.
40. Zavala JA, Amarrenco P, Davis SM, Jones EF, Young D, Macleod MR, et al. Aortic arch atheroma. Int J Stroke. 2006;1(2):74-80.
41. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42(1):227-76. Comprehensive current guidelines for secondary stroke preventions.